What is Bioprotect?
Headquartered in Israel, Bioprotect specializes in the manufacturing of advanced, biodegradable implantable balloons. These devices are engineered to provide essential protection for organs at risk during radiation therapy, effectively reducing side effects and improving patient outcomes. By addressing unmet surgical needs through material science and clinical precision, the company has established itself as a vital contributor to the global life sciences sector. Its market position is defined by a unique intersection of oncology support and surgical intervention, providing a distinct competitive advantage in the medical technology space.
How much funding has Bioprotect raised?
Bioprotect has raised a total of $30.2M across 3 funding rounds:
Series C
$1.7M
Unspecified
$3.5M
Series D
$25M
Series C (2008): $1.7M with participation from Xenia Venture Capital
Unspecified (2017): $3.5M, investors not publicly disclosed
Series D (2020): $25M supported by Accelmed Ventures, KB Investments, Consensus Business Group, and Peregrine Ventures
Key Investors in Bioprotect
Peregrine Ventures
Peregrine is dedicated to advancing medical innovation through global strategic investments, focusing on life science companies at various stages of development.
Xenia Venture Capital
Xenia Venture Capital is a publicly traded hi-tech investment company primarily focused on investing in high tech and med tech sectors in Israel.
Consensus Business Group
Consensus Business Group is a private investment firm that provides strategic capital and operational support to companies within the healthcare and technology sectors.
What's next for Bioprotect?
With the recent influx of capital, Bioprotect is poised to accelerate its research and development initiatives, focusing on the refinement of its existing product pipeline and the potential expansion into new therapeutic applications. The strategic backing from institutional investors provides the necessary runway to navigate regulatory pathways and scale manufacturing capabilities to meet global demand. As the company moves forward, the focus will likely remain on clinical validation and the commercialization of its proprietary technology, ensuring that its biodegradable solutions become a standard of care in radiation oncology departments worldwide. The firm's ability to attract high-caliber investment partners suggests a strong outlook for future market penetration and long-term value creation within the healthcare technology ecosystem.
See full Bioprotect company page
